Total Payments
$53,818
2024 Payments
$31,067
Companies
22
Transactions
347
Medicare Patients
2,974
Medicare Billing
$291,056
Payment Breakdown by Category
Other$32,860 (61.1%)
Food & Beverage$9,188 (17.1%)
Travel$7,408 (13.8%)
Consulting$4,347 (8.1%)
Education$15.16 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,744 | 22 | 46.0% |
| Food and Beverage | $9,188 | 293 | 17.1% |
| Honoraria | $8,116 | 11 | 15.1% |
| Travel and Lodging | $7,408 | 17 | 13.8% |
| Consulting Fee | $4,347 | 2 | 8.1% |
| Education | $15.16 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $30,405 | 59 | $0 (2024) |
| Lexicon Pharmaceuticals, Inc. | $12,701 | 41 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $5,030 | 45 | $0 (2024) |
| Amgen Inc. | $1,111 | 62 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $959.62 | 44 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $725.29 | 12 | $0 (2024) |
| Novo Nordisk Inc | $413.97 | 6 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $390.51 | 6 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $351.15 | 24 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $323.61 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31,067 | 124 | Bayer Healthcare Pharmaceuticals Inc. ($17,350) |
| 2023 | $8,144 | 112 | Lexicon Pharmaceuticals, Inc. ($4,992) |
| 2022 | $8,872 | 66 | Bayer HealthCare Pharmaceuticals Inc. ($7,449) |
| 2021 | $5,735 | 45 | Bayer HealthCare Pharmaceuticals Inc. ($4,816) |
All Payment Transactions
347 individual payment records from CMS Open Payments — Page 2 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/19/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $4.87 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/17/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $27.34 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 09/12/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $144.95 | General |
| Category: Cardiology | ||||||
| 09/03/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: Cardiology | ||||||
| 09/03/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/29/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Consulting Fee | Cash or cash equivalent | $2,254.00 | General |
| Category: Cardio-renal | ||||||
| 08/27/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: DIABETES | ||||||
| 08/26/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $15.56 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 08/22/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $136.77 | General |
| Category: Cardiology | ||||||
| 08/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $5.56 | General |
| Category: Cardio-renal | ||||||
| 08/19/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $21.35 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 08/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $110.75 | General |
| Category: DIABETES | ||||||
| 08/07/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,610.00 | General |
| Category: Cardio-renal | ||||||
| 08/06/2024 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Honoraria | Cash or cash equivalent | $928.00 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
| 08/06/2024 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Honoraria | Cash or cash equivalent | $928.00 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
| 08/06/2024 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Honoraria | Cash or cash equivalent | $928.00 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
| 08/01/2024 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Food and Beverage | In-kind items and services | $120.77 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
| 08/01/2024 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Travel and Lodging | In-kind items and services | $99.83 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
| 07/31/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,771.00 | General |
| Category: Cardio-renal | ||||||
| 07/30/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.23 | General |
| Category: Cardio-renal | ||||||
| 07/30/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $10.09 | General |
| Category: Cardiology | ||||||
| 07/30/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $4.22 | General |
| Category: Cardiology | ||||||
| 07/29/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $759.28 | General |
| Category: Cardio-renal | ||||||
| 07/29/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $759.28 | General |
| Category: Cardio-renal | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 587 | 922 | $172,051 | $45,374 |
| 2022 | 11 | 720 | 1,240 | $242,186 | $64,590 |
| 2021 | 10 | 819 | 1,533 | $321,544 | $91,926 |
| 2020 | 9 | 848 | 1,669 | $321,473 | $89,167 |
Total Patients
2,974
Total Services
5,364
Medicare Billing
$291,056
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 236 | 495 | $102,465 | $24,227 | 23.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 77 | 85 | $21,926 | $6,802 | 31.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 67 | 116 | $15,544 | $5,650 | 36.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 30 | $11,400 | $3,362 | 29.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $6,084 | $1,387 | 22.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 31 | 39 | $4,797 | $1,371 | 28.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 17 | $3,298 | $1,307 | 39.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 63 | 66 | $3,300 | $533.02 | 16.2% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 19 | 21 | $1,197 | $294.00 | 24.6% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 20 | 20 | $1,260 | $265.13 | 21.0% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 20 | 20 | $780.00 | $175.24 | 22.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 239 | 624 | $129,168 | $32,757 | 25.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 93 | 110 | $33,330 | $8,436 | 25.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 78 | 154 | $20,636 | $7,170 | 34.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 47 | 49 | $18,620 | $6,069 | 32.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 29 | 44 | $8,536 | $2,946 | 34.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 26 | 26 | $12,168 | $2,349 | 19.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 21 | 23 | $5,934 | $1,784 | 30.1% |
| 99219 | Initial hospital observation care per day, typically 50 minutes | Facility | 2022 | 14 | 16 | $4,064 | $1,373 | 33.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 143 | 164 | $8,200 | $1,348 | 16.4% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2022 | 15 | 15 | $945.00 | $214.02 | 22.6% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2022 | 15 | 15 | $585.00 | $142.89 | 24.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 240 | 698 | $144,486 | $37,956 | 26.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 115 | 279 | $37,386 | $13,029 | 34.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 117 | 151 | $45,753 | $12,576 | 27.5% |
About Brian Rose, PAC
Brian Rose, PAC is a Physician Assistant healthcare provider based in Raeford, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/16/2017. The National Provider Identifier (NPI) number assigned to this provider is 1578079356.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Brian Rose, PAC has received a total of $53,818 in payments from pharmaceutical and medical device companies, with $31,067 received in 2024. These payments were reported across 347 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($24,744).
As a Medicare-enrolled provider, Rose has provided services to 2,974 Medicare beneficiaries, totaling 5,364 services with total Medicare billing of $291,056. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Physician Assistant
- Location Raeford, NC
- Active Since 12/16/2017
- Last Updated 09/10/2025
- Taxonomy Code 363A00000X
- Entity Type Individual
- NPI Number 1578079356
Products in Payments
- Kerendia (Drug) $30,405
- Inpefa (Drug) $12,504
- XARELTO (Drug) $5,030
- Repatha (Biological) $1,050
- LifeVest (Device) $959.62
- JARDIANCE (Drug) $510.51
- FARXIGA (Drug) $350.90
- LEQVIO (Drug) $281.73
- UPTRAVI (Drug) $281.72
- LOKELMA (Drug) $245.00
- Ozempic (Drug) $224.00
- ELIQUIS (Drug) $181.15
- VERQUVO (Drug) $143.73
- CAMZYOS (Drug) $141.21
- Impella (Device) $132.32
- BRILINTA (Drug) $129.39
- Tactoset (Device) $104.37
- ACUMED (Device) $103.01
- NEXLETOL (Drug) $100.71
- TYVASO (Drug) $100.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Physician Assistant Doctors in Raeford
Stephanie Macklin
Physician Assistant — Payments: $2,999
Physician Assistant $2,999
Ms. Zena Kobaissi, Pa-C, PA-C
Physician Assistant — Payments: $2,358
Physician Assistant $2,358
Mr. James Taylor, Pa, PA
Physician Assistant — Payments: $1,311
Physician Assistant $1,311
Jennifer Wilson, Pa-C, PA-C
Physician Assistant — Payments: $984.43
Physician Assistant $984.43
William Shilkitus, Pac, PAC
Physician Assistant — Payments: $952.80
Physician Assistant $952.80
Mrs. Raquel Mccann, Pa-C, PA-C
Physician Assistant — Payments: $939.62
Physician Assistant $939.62